Share on StockTwits

EXACT Sciences Corp. (NASDAQ:EXAS) VP Graham Peter Lidgard sold 10,288 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $11.96, for a total transaction of $123,044.48. Following the transaction, the vice president now directly owns 102,149 shares of the company’s stock, valued at approximately $1,221,702. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of EXACT Sciences Corp. (NASDAQ:EXAS) traded up 2.20% on Friday, hitting $12.08. The stock had a trading volume of 1,733,041 shares. EXACT Sciences Corp. has a 52 week low of $6.93 and a 52 week high of $14.70. The stock has a 50-day moving average of $11.93 and a 200-day moving average of $12.22. The company’s market cap is $856.7 million.

EXACT Sciences Corp. (NASDAQ:EXAS) last announced its earnings results on Tuesday, October 29th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $1.02 million. During the same quarter in the prior year, the company posted ($0.21) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis.

EXAS has been the subject of a number of recent research reports. Analysts at Maxim Group reiterated a “sell” rating on shares of EXACT Sciences Corp. in a research note to investors on Tuesday, October 29th. Analysts at Wedbush upgraded shares of EXACT Sciences Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $17.38.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.